Kapusta Matthew C sold $1.8M of QURE
Kapusta Matthew C (CEO, Managing Director) sold 35,412 shares of uniQure N.V. (QURE) at an average of $50.02 ($50.00–$50.02, $1.77M total) across 2 trades over 2026-06-24 to 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale of 35,412 shares at ~$50.0162 weighted average across 2026-06-24 to 2026-06-25, totaling ~$1.77M, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor QURE for follow-on insider activity, but this specific filing does not introduce new fundamental catalysts.
What to watch
Insider sales can be offset by other insider buys or by non-informational motives; this filing alone lacks context on total insider activity and does not include any new company guidance.
Background
The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE) by CEO/Managing Director Matthew C Kapusta.
Ticker impact
uniQure CEO Matthew C Kapusta sold about $1.77M of QURE shares in two open-market trades under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect should be small and fade unless accompanied by other news.
Form 4 shows an open-market sale with a stated 10b5-1 plan and a modest insider-sale size relative to typical liquidity; no new operating/clinical/regulatory facts are provided.
Market effects
No sector-wide read-through; this is company-specific insider transaction reporting.
None indicated; filing is US-based disclosure for a Netherlands-domiciled issuer.
Minimal; no deal, trial, or regulatory development affecting broader markets.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view.
Key entities
- issueruniQure N.V.
Subject of the Form 4 insider transaction; CEO Matthew C Kapusta sold shares under a 10b5-1 plan.
- insiderKapusta Matthew C
CEO, Managing Director; reported open-market sale of 35,412 QURE shares.